Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1247
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 937–948 of 1,247 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

NCT04136002
Site status not listed — check the official record
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Not listed
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
45 Years to 84 Years
Enrollment
44,467 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
271
States / cities
Anniston, Alabama • Guntersville, Alabama • Huntsville, Alabama + 217 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

NCT06141486
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Placebo, MRI contrast-enhancing agents
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

NCT03574571
Site status not listed — check the official record
View directory record Official record
Conditions
Prostate Cancer
Interventions
Docetaxel 75 mg/m2, Docetaxel 60 mg/m2, Radium-223
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
40
States / cities
Gilbert, Arizona • New Haven, Connecticut • Newark, Delaware + 32 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Recruiting Not applicable Interventional

Exploring Water-free Sodium Storage

NCT06872645
Status at this site: Recruiting
View directory record Official record
Conditions
Peritoneal Dialysis, Heart Failure
Interventions
5% Dextrose/Water, 1.5% standard PD fluid
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple Myeloma

NCT05002816
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Belantamab mafodotin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Health-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For Health

NCT05218980
Site status not listed — check the official record
View directory record Official record
Conditions
Healthy Diet, Cholesterol, Healthy Lifestyle, Healthy Nutrition
Interventions
Olives
Dietary Supplement
Lead sponsor
Yale University
Other
Eligibility
18 Years to 23 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Recruiting Phase 2 Interventional

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

NCT06993675
Status at this site: Recruiting
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Talquetamab, Teclistamab
Drug
Lead sponsor
Noffar Bar
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
New Haven, Connecticut • Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Active, not recruiting Not applicable Interventional Results available

Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS

NCT02926911
Site status not listed — check the official record
View directory record Official record
Conditions
DCIS, Ductal Carcinoma in Situ
Interventions
Surgery, Active Monitoring
Other
Lead sponsor
Alliance Foundation Trials, LLC.
Other
Eligibility
40 Years to 99 Years · Female only
Enrollment
997 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
141
States / cities
Anchorage, Alaska • Phoenix, Arizona • Duarte, California + 117 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Active, not recruiting No phase listed Observational

Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial

NCT07226622
Site status not listed — check the official record
View directory record Official record
Conditions
Wilson Disease
Interventions
Not listed
Lead sponsor
Prime Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
7
States / cities
Los Angeles, California • Sacramento, California • New Haven, Connecticut + 4 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Active, not recruiting Phase 2 Interventional

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

NCT06384261
Site status not listed — check the official record
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
Cusatuzumab, Venetoclax, Azacitidine
Drug
Lead sponsor
OncoVerity, Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
20
States / cities
Gilbert, Arizona • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046
Status at this site: Recruiting
View directory record Official record
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 11:52 PM EDT
Not yet recruiting Not applicable Interventional

Human Milk Concentrating Device to Optimize Mother's Own Milk

NCT07576972
Site status not listed — check the official record
View directory record Official record
Conditions
Preterm Infant Health, Premature Babies
Interventions
Human Milk Concentration Device, Standard of Care Fortified Feeding
Device · Other
Lead sponsor
Mother's Milk is Best
Industry
Eligibility
32 Weeks to 35 Weeks
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 11:52 PM EDT

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.